• Publications
  • Influence
Centrality of Striatal Cholinergic Transmission in Basal Ganglia Function
Work over the past two decades revealed a previously unexpected role for striatal cholinergic interneurons in the context of basal ganglia function. The recognition that these interneurons areExpand
  • 89
  • 8
  • PDF
Cholinergic Dysfunction Alters Synaptic Integration between Thalamostriatal and Corticostriatal Inputs in DYT1 Dystonia
Projections from thalamic intralaminar nuclei convey sensory signals to striatal cholinergic interneurons. These neurons respond with a pause in their pacemaking activity, enabling synapticExpand
  • 73
  • 6
  • PDF
Metabotropic glutamate receptor subtype 4 selectively modulates both glutamate and GABA transmission in the striatum: implications for Parkinson’s disease treatment
Alterations of striatal synaptic transmission have been associated with several motor disorders involving the basal ganglia, such as Parkinson’s disease. For this reason, we investigated the role ofExpand
  • 53
  • 4
Anticholinergic drugs rescue synaptic plasticity in DYT1 dystonia: Role of M1 muscarinic receptors
Broad‐spectrum muscarinic receptor antagonists have represented the first available treatment for different movement disorders such as dystonia. However, the specificity of these drugs and theirExpand
  • 56
  • 2
Activation of 5-HT6 receptors inhibits corticostriatal glutamatergic transmission
We investigated the effect of 5-HT6 receptor subtype activation on glutamatergic transmission by means of whole-cell patch-clamp electrophysiological recordings from medium spiny neurons of theExpand
  • 31
  • 2
Distinct roles of group I mGlu receptors in striatal function
In the recent past, evidence accumulated in favour of a central role of group I metabotropic glutamate (mGlu) receptors, mGlu1 and mGlu5, in the modulation of cell excitability both of striatalExpand
  • 30
  • 2
Early synaptic dysfunction in Parkinson's disease: Insights from animal models
The appearance of motor manifestations in Parkinson's disease (PD) is invariably linked to degeneration of nigral dopaminergic neurons of the substantia nigra pars compacta. Traditional views on PDExpand
  • 68
  • 1
Homeostatic changes of the endocannabinoid system in Parkinson's disease
Endocannabinoids (eCBs) are endogenous lipids that bind principally type‐1 and type‐2 cannabinoid (CB1 and CB2) receptors. N‐Arachidonoylethanolamine (AEA, anandamide) and 2‐arachidonoylglycerolExpand
  • 41
  • 1
Efficacy and safety profile of prolonged release oxycodone in combination with naloxone (OXN PR) in Parkinson’s disease patients with chronic pain
Pain is a relevant and often underestimated non-motor symptom affecting the quality of life of patients with Parkinson’s disease (PD). Although some pain symptoms can be effectively treated byExpand
  • 31
  • 1
PINK1 heterozygous mutations induce subtle alterations in dopamine‐dependent synaptic plasticity
Homozygous or compound heterozygous mutations in the phosphatase and tensin homolog‐induced putative kinase 1 (PINK1) gene are causative of autosomal recessive, early onset Parkinson's disease.Expand
  • 30
  • 1